Nexstim registers 840,000 new shares after €3.8M Eiffel and Brainlab investment

What's the deal? Finnish medical technology company Nexstim has registered 840,000 new shares with the Finnish Trade Register following a €3.8M investment. The bulk — €3.4M — came from Eiffel Investment GroupDealroom has a profile for this one. Try Dealroom → via a directed share issue, while BrainlabDealroom has a profile for this one. Try Dealroom → SE contributed an additional €0.4M.

The registration happened in two tranches. First, 502,500 shares tied to the Eiffel and Brainlab investments were registered on May 18 and began trading on May 20. A second batch of 337,463 shares — from option rights exercised by Eiffel and other holders — was registered on May 22 and started trading on May 25.

Nexstim's total share count now stands at 8,074,859.

Why now? Nexstim is a growth-oriented medtech company that develops navigated transcranial magnetic stimulation (nTMS) technology for brain diagnostics and therapy. It sells the NBS System 6, which is FDA-cleared for pre-surgical brain mapping and for treating major depressive disorder and obsessive compulsive disorder. Fresh capital likely supports the company's commercialisation push across these markets.

What could go wrong? Directed share issues dilute existing shareholders. Nexstim's total share count jumped significantly, and further option exercises could dilute holdings even more. As a small-cap listed on Nasdaq First North Growth Market Finland, the company also faces liquidity risk — thinly traded stocks can see outsized price swings on modest volume.

The signal: Nexstim, classified as a "breakout"-stage company on Dealroom, is drawing capital from both a dedicated investment fund in Eiffel and a strategic corporate backer in Brainlab — a combination that suggests the technology is gaining commercial credibility beyond pure financial speculation. Eiffel's decision to exercise option rights on top of its €3.4 million directed issue points to a conviction bet on Nexstim's navigated TMS platform at a time when non-invasive neuromodulation therapies are moving deeper into mainstream psychiatric and surgical care.

Read more: hk.marketscreener.com